{"database": "lobbying", "table": "lobbying_activities", "rows": [[2343428, "2c8df2c3-304b-4428-96ad-34481420fbdf", "Q3", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2019, "third_quarter", "PHA", "Issues related to prescription drug value. \n\nS.2543: Prescription Drug Pricing Reduction Act of 2019.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nBiosimilars.\n\n340B issues.\n\nPatents and protection of intellectual property issues.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office", 60000, null, 0, 0, "2019-10-16T08:46:17.793000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2343428"], "units": {}, "query_ms": 29.4667009729892, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}